Assessment and monitoring of patients receiving chemotherapy for multiple myeloma: strategies to improve outcomes

References

• KyleRAGertzMAWitzigTEReview of 1027 patients with newly diagnosed multiple myelomaMayo Clin Proc2003781213312528874
   PubMed Web of Science ®Google Scholar
• Cancer IAfRoGLOBOCAN 2012 Estimated Cancer Incidence, Mortality and Prevalence Worldwide Available from: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx?country=900Accessed April 13, 2016
   Google Scholar
• LandgrenORajkumarSVPfeifferRMObesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white womenBlood201011671056105920421448
   PubMed Web of Science ®Google Scholar
• RajkumarSVDimopoulosMAPalumboAInternational Myeloma Working Group updated criteria for the diagnosis of multiple myelomaLancet Oncol20141512e538e54825439696
   PubMed Web of Science ®Google Scholar
• FaimanBMyeloma genetics and genomics: practice implications and future directionsClin Lymphoma Myeloma Leuk201414643644025127058
   PubMed Web of Science ®Google Scholar
• FonsecaRMongeJMyeloma: Classification and risk assessmentSemin Oncol201340555456624135400
   PubMed Web of Science ®Google Scholar
• LandgrenOMorganGJBiological frontiers in multiple myeloma: from biomarker identification to clinical practiceClin Cancer Res Epub20131122
   Web of Science ®Google Scholar
• Van WierSBraggioEBakerAHypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myelomaHaematologica Epub2013528
   Web of Science ®Google Scholar
• Vincent RajkumarSMultiple myeloma: 2014 Update on diagnosis, risk-stratification, and managementAm J Hematol20148910999100925223428
   PubMed Web of Science ®Google Scholar
• ShahJJAbonourRDurieBGMConnect MM®–the multiple myeloma (MM) disease registry: interim analysis of overall survival and outcomes in patients with high-risk diseaseBlood2014124212106
   Google Scholar
• TerposEMoulopoulosLADimopoulosMAAdvances in imaging and the management of myeloma bone diseaseJ Clin Oncol201129141907191521483016
   PubMed Web of Science ®Google Scholar
• RoodmanGDMechanisms of bone metastasisN Engl J Med2004350161655166415084698
   PubMed Web of Science ®Google Scholar
• RajeNRoodmanGDAdvances in the biology and treatment of bone disease in multiple myelomaClin Cancer Res20111761278128621411443
   PubMed Web of Science ®Google Scholar
• TerposEMorganGDimopoulosMAInternational Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone diseaseJ Clin Oncol201331182347235723690408
   PubMed Web of Science ®Google Scholar
• DimopoulosMAHillengassJUsmaniSRole of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statementJ Clin Oncol201533665766425605835
   PubMed Web of Science ®Google Scholar
• DurieBGMHarousseauJLMiguelJSInternational uniform response criteria for multiple myelomaLeukemia20062091467147316855634
   PubMed Web of Science ®Google Scholar
• LandgrenOGraubardBIKatzmannJARacial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination SurveyLeukemia20142871537154224441287
   PubMed Web of Science ®Google Scholar
• RajkumarSVKyleRATherneauTMSerum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significanceBlood2005106381281715855274
   PubMed Web of Science ®Google Scholar
• KatzmannJAClarkRKyleRASuppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUSLeukemia201327120821222781594
   PubMed Web of Science ®Google Scholar
• KyleRADurieBGMRajkumarSVMonoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and managementLeukemia20102461121112720410922
   PubMed Web of Science ®Google Scholar
• LarsenJTKumarSKDispenzieriAKyleRAKatzmannJARajkumarSVSerum free light chain ratio as a biomarker for high-risk smoldering multiple myelomaLeukemia201327494194623183428
   PubMed Web of Science ®Google Scholar
• RajkumarSVEvolving diagnostic criteria for multiple myelomaHematology Am Soc Hematol Educ Program20152015127227826637733
   PubMed Web of Science ®Google Scholar
• WaxmanAMickRGarfallAModeling the risk of progression in smoldering multiple myelomaJ Clin Oncol2014325s (suppl):abstract 8607
   Web of Science ®Google Scholar
• DispenzieriAKyleRMerliniGInternational Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disordersLeukemia200823221522419020545
   PubMed Web of Science ®Google Scholar
• DispenzieriAKyleRAKatzmannJAImmunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myelomaBlood2008111278578917942755
   PubMed Web of Science ®Google Scholar
• KastritisETerposEMoulopoulosLExtensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic diseaseLeukemia201327494795323183429
   PubMed Web of Science ®Google Scholar
• HillengassJWeberMAKilkKPrognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significanceLeukemia201428117417823958921
   PubMed Web of Science ®Google Scholar
• DurieBGSalmonSEA clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survivalCancer1975368428541182674
   PubMed Web of Science ®Google Scholar
• GreippPRMiguelJSDurieBGMInternational staging system for multiple myelomaJ Clin Oncol200523153412342015809451
   PubMed Web of Science ®Google Scholar
• LonialSAndersonKCAssociation of response endpoints with survival outcomes in multiple myelomaLeukemia201428225826823868105
   PubMed Web of Science ®Google Scholar
• FonsecaRBarlogieBBatailleRGenetics and cytogenetics of multiple myelomaCancer Res20046441546155814989251
   PubMedGoogle Scholar
• PalumboAAvet-LoiseauHOlivaSRevised international staging system for multiple myeloma: a report from International Myeloma Working GroupJ Clin Oncol Epub201583
   Web of Science ®Google Scholar
• NCCNNCCN Multiple Myeloma Clinical Practice Guidelines in Oncology v2.2016The Complete Library of NCCN Clinical Practice Guidelines in OncologyJenkintown, PAAuthor2016
   Google Scholar
• KumarSKRajkumarSVDispenzieriAImproved survival in multiple myeloma and the impact of novel therapiesBlood200811152516252017975015
   PubMed Web of Science ®Google Scholar
• RichardsonPGBarlogieBBerensonJA phase 2 study of bortezomib in relapsed, refractory myelomaN Engl J Med2003348262609261712826635
   PubMed Web of Science ®Google Scholar
• RichardsonPGSonneveldPSchusterMWAssessment of Proteasome Inhibition for Extending Remissions (APEX) InvestigatorsBortezomib or high-dose dexamethasone for relapsed multiple myelomaN Engl J Med2005352242487249815958804
   PubMed Web of Science ®Google Scholar
• RichardsonPGBloodEMitsiadesCSA randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myelomaBlood2006108103458346416840727
   PubMed Web of Science ®Google Scholar
• RichardsonPGSonneveldPSchusterMExtended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialBlood2007110103557356017690257
   PubMed Web of Science ®Google Scholar
• San MiguelJFSchlagRKhuagevaNKVISTA Trial InvestigatorsBortezomib plus melphalan and prednisone for initial treatment of multiple myelomaN Engl J Med2008359990691718753647
   PubMed Web of Science ®Google Scholar
• RichardsonPJagannathSHusseinMSafety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myelomaBlood2009114477277819471019
   PubMed Web of Science ®Google Scholar
• RichardsonPGSchlossmanRLAlsinaMPANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myelomaBlood2013122142331233723950178
   PubMed Web of Science ®Google Scholar
• RichardsonPGSiegelDSVijRPomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 studyBlood2014123121826183224421329
   PubMed Web of Science ®Google Scholar
• LonialSDimopoulosMPalumboAELOQUENT-2 InvestigatorsElotuzumab therapy for relapsed or refractory multiple myelomaN Engl J Med2015373762163126035255
   PubMed Web of Science ®Google Scholar
• StewartAKRajkumarSVDimopoulosMAASPIRE InvestigatorsCarfilzomib, lenalidomide, and dexamethasone for relapsed multiple myelomaN Engl J Med2015372214215225482145
   PubMed Web of Science ®Google Scholar
• BenboubkerLDimopoulosMADispenzieriAFIRST Trial TeamLenalidomide and dexamethasone in transplant-ineligible patients with myelomaN Engl J Med20143711090691725184863
   PubMed Web of Science ®Google Scholar
• RichardsonPGJagannathSMoreauPFinal results for the 1703 phase 1b/2 study of elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma56th ASH Annual Meeting and ExpositionDecember 6–9, 2014San Francisco, CA1242014
   Google Scholar
• RichardsonPWellerELonialSLenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma [abstract 92]Blood2010116567968620385792
   PubMed Web of Science ®Google Scholar
• DimopoulosMAKastritisEChristoulasDTreatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapiesLeukemia201024101769177820739955
   PubMed Web of Science ®Google Scholar
• DurieBHoeringARajkumarSVBortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT): results of the randomized phase III trial SWOG S0777Blood20151262325
   Web of Science ®Google Scholar
• MoreauPPylypenkoHGrosickiSSubcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority studyLancet Oncol201112543144021507715
   PubMed Web of Science ®Google Scholar
• FaimanBElsonPSmithMNeuropathy and efficacy of weekly subcutaneous bortezomib in myeloma and AL amyloidosisBlood2013122211975
   Web of Science ®Google Scholar
• RajkumarSVJacobusSCallanderNSEastern Cooperative Oncology GroupLenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trialLancet Oncol2010111293719853510
   PubMed Web of Science ®Google Scholar
• WeberDMChenCNiesvizkyRMultiple Myeloma (009) Study InvestigatorsLenalidomide plus dexamethasone for relapsed multiple myeloma in North AmericaN Engl J Med2007357212133214218032763
   PubMed Web of Science ®Google Scholar
• WangMDimopoulosMAChenCLenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposureBlood2008112124445445118799726
   PubMed Web of Science ®Google Scholar
• PalumboARajkumarSVSan MiguelJFInternational Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationJ Clin Oncol201432658760024419113
   PubMed Web of Science ®Google Scholar
• LaroccaAPalumboAHow I treat fragile myeloma patientsBlood Epub2015831
   Web of Science ®Google Scholar
• ChenNLauHKongLPharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysisJ Clin Pharmacol200747121466147517954615
   PubMed Web of Science ®Google Scholar
• PalumboABringhenSLudwigHPersonalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)Blood2011118174519452921841166
   PubMed Web of Science ®Google Scholar
• DimopoulosMAMoreauPPalumboAENDEAVOR investigatorsCarfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre studyLancet Oncol2016171273826671818
   PubMed Web of Science ®Google Scholar
• SiegelDMartinTWangMA phase 2 study of single-agent carfilzomib (PX-171003-A1) in patients with relapsed and refractory multiple myelomaBlood2012120142817282522833546
   PubMed Web of Science ®Google Scholar
• JagannathSVijRStewartAKAn open-label single-arm pilot phase II study (PX-171003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myelomaClin Lymphoma Myeloma Leuk201212531031823040437
   PubMed Web of Science ®Google Scholar
• VijRSiegelDJagannathSAn open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomibBr J Haematol2012158673974822845873
   PubMed Web of Science ®Google Scholar
• VijRWangMKaufmanJLAn open-label, single-arm, phase 2 (PX-171004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myelomaBlood2012119245661567022555973
   PubMed Web of Science ®Google Scholar
• BadrosAZVijRMartinTCarfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safetyLeukemia Epub2013131
   Web of Science ®Google Scholar
• PalumboARossiDBringhenSWeekly carfilzomib, cyclophosphamide and dexamethasone (wCCd) in newly diagnosed multiple myeloma patients: A phase I–II study56th ASH Annual Meeting and ExpositionDecember 6–9, 2014San Francisco, CA1242014
   Google Scholar
• SquiffletPMichielsSSiegelDSVijRRoSBuyseMEMultivariate modelling reveals evidence of a dose-response relationship in phase 2 studies of single-agent carfilzomib [abstract]Blood201111821 Abstract 1877
   Web of Science ®Google Scholar
• LendvaiNLandauHLesokhinAPhase II study of infusional carfilzomib in patients with relapsed or refractory multiple myelomaBlood2012120 Abstract 947
   Google Scholar
• StadtmauerEShahJAbonourRCarfilzomib, pomalidomide and dexamethasone (CPomd) for relapsed/refractory multiple myeloma (RRMM): a phase I/II trialClin Lymphoma Myeloma Leuk201313Supplement 1P250
   Google Scholar
• ShahJThomasSWeberDPhase 1/1b study of the efficacy and safety of the combination of panobinostat + carfilzomib in patients with relapsed and/or refractory multiple myelomaBlood2012120 Abstract 4081
   Web of Science ®Google Scholar
• BerdejaJHartLLamarRMurphyPMorganSIFlinnIPhase I/II study of panobinostat and carfilzomib in patients (pts) with relapsed or refractory multiple myeloma (MM), interim phase I safety analysisBlood2012120 Abstract 4048
   Google Scholar
• KaufmanJZimmermanTJakubowiakAPhase I study of the combination of carfilzomib and panobinostat for patients with relapsed and refractory myeloma: a multicenter MMRC clinical trialHaematologica201398Supplement 1 Abstract P771
   Google Scholar
• AmgenKYPROLIS™ (carfilzomib) for Injection, for intravenous useSouth San Francisco, CA2016
   Google Scholar
• ColsonKTreatment-related symptom management in patients with multiple myeloma: a reviewSupportive Care Cancer201523514311445
   PubMed Web of Science ®Google Scholar
• CorporationCPomalidomide (Pomalyst) [package insert]Summit, NJAuthor2013
   Google Scholar
• LacyMQLaPlantBRLaumannKMPomalidomide, bortezomib and dexamethasone (PVD) for patients with relapsed lenalidomide refractory multiple myeloma (MM)56th ASH Annual Meeting and ExpositionDecember 6–9, 2014San Francisco, CA1242014
   Google Scholar
• BazRMartinTGAlsinaMPomalidomide, cyclophosphamide, and dexamethasone is superior to pomalidomide and dexamethasone in relapsed and refractory myeloma: results of a multicenter randomized phase II study56th ASH Annual Meeting and ExpositionDecember 6–9, 2014San Francisco, CA1242014
   Google Scholar
• BadrosAZKocogluMHMaNA phase II study of anti PD-1 antibody pembrolizumab, pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM)Blood201512623506
   Web of Science ®Google Scholar
• ChariALonialSSuvannasankhaAOpen-label, multicenter, phase 1b study of daratumumab in combination with pomalidomide and dexamethasone in patients with at least 2 lines of prior therapy and relapsed or relapsed and refractory multiple myelomaBlood20151262350826082451
   PubMed Web of Science ®Google Scholar
• San-MiguelJFHungriaVTYoonSSPanobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trialLancet Oncol201415111195120625242045
   PubMed Web of Science ®Google Scholar
• RichardsonPGHungriaVTYoonSSPanobinostat plus bortezomib and dexamethasone in relapsed/relapsed and refractory myeloma: outcomes by prior treatmentBlood Epub2015122
   Google Scholar
• MoreauPMassziTGrzaskoNIxazomib, an investigational oral proteasome inhibitor (PI), in combination with lenalidomide and dexamethasone (IRd), significantly extends progression-free survival (PFS) for patients (Pts) with relapsed and/or refractory multiple myeloma (RRMM): the phase 3 tourmaline-MM1 study (NCT01564537)Blood201512623727
   Web of Science ®Google Scholar
• UsmaniSWeissBBahlisNJClinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myelomaBlood20151262329
   Web of Science ®Google Scholar
• PlesnerTArkenauH-TGimsingPDaratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: updated results of a phase 1/2 study (GEN503)Blood201512623507
   Google Scholar
• JanssenDaratumumab (DARZALEX) injection2015
   Google Scholar
• HsiEDSteinleRBalasaBCS1, a potential new therapeutic antibody target for the treatment of multiple myelomaClin Cancer Res20081492775278418451245
   PubMed Web of Science ®Google Scholar
• EganJBShiC-XTembeWWhole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tidesBlood201212051060106622529291
   PubMed Web of Science ®Google Scholar
• KeatsJJChesiMEganJBClonal competition with alternating dominance in multiple myelomaBlood201212051067107622498740
   PubMed Web of Science ®Google Scholar
• Lohr JensGStojanovPCarter ScottLWidespread genetic heterogeneity in multiple myeloma: implications for targeted therapyCancer Cell20142519110124434212
   PubMed Web of Science ®Google Scholar
• RajeNSWillenbacherWHungriaVEvaluating results from the multiple myeloma subset of patients treated with denosumab or zoledronic acid (ZA) in a randomized phase III studyASCO Meeting Abstracts20133115_suppl8589
   Google Scholar
• TerposEBerensonJRajeNRoodmanGDManagement of bone disease in multiple myelomaExpert Rev Hematol20147111312524433088
   PubMed Web of Science ®Google Scholar
• BerensonJREfficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study GroupN Engl J Med19963344884938559201
   PubMed Web of Science ®Google Scholar
• MachadoMCruzLSTannusGFonsecaMEfficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trialsClin Ther200931596297919539097
   PubMed Web of Science ®Google Scholar
• AaproMSaadFCostaLOptimizing clinical benefits of bisphosphonates in cancer patients with bone metastasesOncologist201015111147115821051658
   PubMed Web of Science ®Google Scholar
• GimsingPCarlsonKTuressonIEffect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trialLancet Oncol2010111097398220863761
   PubMed Web of Science ®Google Scholar
• MorganGJDaviesFEGregoryWMNational Cancer Research Institute Haematological Oncology Clinical Study GroupFirst-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trialLancet201037697571989199921131037
   PubMed Web of Science ®Google Scholar
• MiceliTColsonKFaimanBMillerKTarimanJInternational Myeloma Foundation Nurse Leadership BoardMaintaining bone health in patients with multiple myelomaClin J Oncol Nurs201115923
   Web of Science ®Google Scholar
• RomeSIJenkinsBSLillebyKEInternational Myeloma Foundation Nurse Leadership BoardMobility and safety in the multiple myeloma survivor: survivorship care plan of the International Myeloma Foundation Nurse Leadership BoardClin J Oncol Nurs201115Suppl4152
   Google Scholar
• BilottiEFaimanBRichardsTTarimanJDMiceliTRomeSInternational Myeloma Foundation Nurse Leadership BoardSurvivorship care guidelines for patients living with multiple myeloma: consensus statements of the International Myeloma Foundation Nurse Leadership BoardClin J Oncol Nurs201115Suppl5821816706
   PubMed Web of Science ®Google Scholar
• FaimanBManganPSpongJETarimanJDThe International Myeloma Foundation Nurse Leadership BoardRenal complications in multiple myeloma and related disorders: survivorship care plan of the IMF Nurse Leadership BoardClin J Oncol Nurs201115Suppl667621816711
   PubMed Web of Science ®Google Scholar
• FaimanBSidanaSElsonPLenalidomide related diarrhea correlates with survival in multiple myelomaBlood2013122215397
   Web of Science ®Google Scholar
• NucciMAnaissieEInfections in patients with multiple myeloma in the era of high-dose therapy and novel agentsClin Infect Dis20094981211122519769539
   PubMed Web of Science ®Google Scholar
• KalambokisGNChristouLTsianosEVMultiple myeloma presenting with an acute bacterial infectionInt J Lab Hematol200931437538319486365
   PubMed Web of Science ®Google Scholar
• DurieBGKyleRABelchAScientific Advisors of the International Myeloma FoundationMyeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma FoundationHematol J20034637939814671610
   PubMedGoogle Scholar
• PreventionCDCcontrol of influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP)MMWR2010598
   Google Scholar
• VisovskyCHaasMFaimanBNurse self-evaluation of assessment of chemotherapy-induced peripheral neuropathy in patients with cancerJ Adv Pract Oncol2012331932525031961
   PubMedGoogle Scholar
• RichardsonPGDelforgeMBeksacMManagement of treatment-emergent peripheral neuropathy in multiple myelomaLeukemia201226459560822193964
   PubMed Web of Science ®Google Scholar
• TarimanJLoveGMcCullaghESandiferSIMF Nurse Leadership BoardPeripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF nurse leadership boardClin J Oncol Nurs200812293518490255
   PubMed Web of Science ®Google Scholar
• BroylAJongenJLMSonneveldPGeneral aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myelomaSemin Hematol201249324925722726548
   PubMed Web of Science ®Google Scholar
• OncologyTBortezomib (Velcade) [package insert]Cambridge, MAAuthor2015
   Google Scholar
• PrestonDShapiroBElectromyography and Neuromuscular Disorders: Clinical-Electrophysiologic Correlations2 edBostonButterworth-Heinemann2005
   Google Scholar
• PonceletANAn algorithm for the evaluation of peripheral neuropathyAm Fam Physician19981557755764
   Google Scholar
• CalhounEWelshmanEChangCPsychometric Evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) questionnaire for patients receiving systemic chemotherapyInt J Gynecol Cancer20031374174814675309
   PubMed Web of Science ®Google Scholar
• BazRAlemanyCGreenRHusseinMAPrevalence of vitamin B12 deficiency in patients with plasma cell dyscrasiasCancer2004101479079515305411
   PubMed Web of Science ®Google Scholar
• BadrosAGoloubevaODalalJSNeurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literatureCancer200711051042104917654660
   PubMed Web of Science ®Google Scholar
• PalumboARajkumarSVDimopoulosMAInternational Myeloma Working GroupPrevention of thalidomide- and lenalidomide-associated thrombosis in myelomaLeukemia200822241442318094721
   PubMed Web of Science ®Google Scholar
• BazRLiLKottke-MarchantKThe role of aspirin in the prevention of thrombotic complications of thalidomide and anthra-cycline-based chemotherapy for multiple myelomaMayo Clin Proc200580121568157416342649
   PubMed Web of Science ®Google Scholar
• LymanGHBohlkeKKhoranaAAVenous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014J Clin Oncol201533665465625605844
   PubMed Web of Science ®Google Scholar
• van EsNBüllerHRUsing direct oral anticoagulants (DOACs) in cancer and other high-risk populationsHematology Am Soc Hematol Educ Program20152015112513126637711
   PubMed Web of Science ®Google Scholar
• DenlingerCSCarlsonRWAreMSurvivorship: introduction and definition. Clinical practice guidelines in oncologyJ Natl Compr Canc Netw2014121344524453291
   PubMed Web of Science ®Google Scholar
• National Cancer InstituteAbout cancer survivorship research: survivorship definitions2014 Available from: http://cancercontrol.cancer.gov/ocs/Accessed August 22, 2014
   Google Scholar
• TaylorKMonterossoLSurvivorship care plans and treatment summaries in adult patients with hematologic cancer: an integrative literature reviewOncol Nurs Forum201542328329125901380
   PubMed Web of Science ®Google Scholar
• BilottiEGleasonCMcNeillAInternational Myeloma Foundation Nurse Leadership BoardRoutine health maintenance in patients living with multiple myeloma: survivorship care plan of the International Myeloma Foundation Nurse Leadership BoardClin J Oncol Nurs201115Supp254021816708
   PubMed Web of Science ®Google Scholar
• FaimanBBilottiEManganPRogersKSteroid-associated side effects in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership BoardClinical Journal of Oncology Nursing200812536218490257
   PubMed Web of Science ®Google Scholar
• RomeSDossDMillerKWestphalJThromboembolic events associated with novel therapies in patients with multiple myeloma: Consensus statement of the IMF Nurse Leadership BoardClinical Journal of Oncology Nursing2008122128
   Web of Science ®Google Scholar
• RichardsTBrigleKJPalliative care in multiple myelomaJ Adv Pract Oncol201673143
   Google Scholar